Ivo de Nooijer is director at Orfenix, which specialises in developing medicines that originate in academic research, ensuring they reach patients at an accessible price while maintaining returns for investors. By combining academic expertise with regulatory and clinical development know-how, Orfenix builds collaborative partnerships between academia and industry. With degrees in Biopharmaceutical Sciences, Dutch Law and History from Leiden University, Ivo has built a career at the intersection of science, law and societal impact, focusing on how discoveries can be translated into benefits for patients. He combines deep experience in technology transfer, intellectual property and licensing with an understanding of the life sciences, and has worked extensively with universities, medical centres and public organisations on socially responsible licensing and impact-driven knowledge transfer. Committed to collaboration and patient access, Ivo believes that well-designed public–private partnerships can offer a sustainable way to bring medicines to those who need them most.